In AML, research has found that hypomethylating agents (HMAs) can upregulate CD70 expression in LSCs by reducing CD70 promoter methylation and enhance stem cell self‐renewal and survival by activating the CD70/CD27 signalling pathway.128. This evidence concerns the gene CD27 and acute myeloid leukemia.